Abstract Number: 170 • 2019 ACR/ARP Annual Meeting
Evaluating an Illustrated Storybook for Children with Juvenile Idiopathic Arthritis
Background/Purpose: While juvenile idiopathic arthritis (JIA) is a common pediatric rheumatic disease, there is a lack of available child-friendly patient education materials. An illustrated storybook…Abstract Number: 1174 • 2019 ACR/ARP Annual Meeting
Prevalence of Subclinical Sacroiliitis in Young Patients with Inflammatory Bowel Disease Revealed by Entero-MRI
Background/Purpose: Sacroiliitis is one of the extraintestinal manifestations associated with inflammatory bowel disease (IBD), and may be underdiagnosed especially in the pediatric age. MR-enterography (Entero-MRI)…Abstract Number: 2705 • 2019 ACR/ARP Annual Meeting
Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis
Background/Purpose: Mental health disorders are thought to be common in patients with rheumatic disease, but studies examining behavioral issues in patients with juvenile idiopathic arthritis…Abstract Number: 187 • 2019 ACR/ARP Annual Meeting
Epidemiology of JIA-Associated Uveitis: Environmental Factors and Disease Characteristics of a JIA-Associated Uveitis Cohort
Background/Purpose: JIA-associated uveitis (JIA-U) is the most prevalent extra-articular manifestation of JIA and the most common type of uveitis in children. To date, environmental factors…Abstract Number: 1201 • 2019 ACR/ARP Annual Meeting
Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?
Background/Purpose: Wait time to pediatric rheumatology care for patients with Juvenile Idiopathic Arthritis (JIA) is a nationally endorsed quality measure in Canada. Target wait times…Abstract Number: 2706 • 2019 ACR/ARP Annual Meeting
Association of Body Mass Index with Juvenile Idiopathic Arthritis Disease Activity: A Portuguese and Brazilian Collaborative Analysis with Data from Reuma.pt Registry
Background/Purpose: In adults with Rheumatoid Arthritis, obesity has been associated with higher disease activity. However, in Juvenile Idiopathic Arthritis (JIA), the influence of body mass…Abstract Number: 188 • 2019 ACR/ARP Annual Meeting
The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood
Background/Purpose: Upon transitioning from pediatric to adult care, many patients with JIA are labeled as having RA, despite the two diagnoses being distinct in care…Abstract Number: 1814 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era
Background/Purpose: After nearly two decades from the start of the Biologic era, systematic analyses of patients with juvenile idiopathic arthritis (JIA) have shown a high…Abstract Number: 2710 • 2019 ACR/ARP Annual Meeting
Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to membrane and soluble IL-6 receptor-α. Sarilumab is approved for adults with rheumatoid arthritis (RA) and is being…Abstract Number: 255 • 2019 ACR/ARP Annual Meeting
Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers
Background/Purpose: In 2018 an international task force published a recommended Treat to Target (T2T) approach to juvenile idiopathic arthritis (JIA) treatment. In February 2019, 17…Abstract Number: 1817 • 2019 ACR/ARP Annual Meeting
Arthropathy of Down Syndrome: An Under-diagnosed Inflammatory Joint Disease That Warrants a Name Change
Background/Purpose: Incidence and prevalence of arthropathy of Down syndrome (A-DS) is increased. It is rarely recognised at onset and remains under-diagnosed. Children with A-DS are therefore…Abstract Number: 2711 • 2019 ACR/ARP Annual Meeting
Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: In recent years, juvenile idiopathic arthritis (JIA) treatment options have expanded to include biologics such as tumor necrosis factor inhibitors (TNFi) and non-TNF inhibitors…Abstract Number: 773 • 2019 ACR/ARP Annual Meeting
Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation
Background/Purpose: Progression of Juvenile Idiopathic Arthritis (JIA) can lead to growth disturbances in affected joints. Fibroblast-like synoviocytes (FLS) play a key role in the pathogenesis…Abstract Number: 1883 • 2019 ACR/ARP Annual Meeting
Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients
Background/Purpose: Despite a broad range of available therapeutics, pain remains poorly treated in many juvenile idiopathic arthritis (JIA) patients1-2. For some patients, the level of pain…Abstract Number: 2712 • 2019 ACR/ARP Annual Meeting
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 19
- Next Page »